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ABSTRACT 
 
Cardiovascular disease is the leading cause of death worldwide.  
Coronary Artery Disease (CAD) accounts for the majority of those 
deaths.  Observational studies have identified risk factors that 
have been helpful in lowering the death rate, including 
hypertension, high cholesterol, diabetes, smoking, physical 
inactivity and poor diet. The effects of these risk factors on 
CAD remain unclear.  To clarify the effect of three amino acids, 
alanine, glutamine, and glycine on CAD I applied a two sample 
Mendelian randomization analysis to extensively genotyped 
observational data.  In a sample with up to 184,000 individuals 
and approximately 60,000 controls, SNPs that reached genome wide 
significance with each amino acid were identified.   Linkage 
equilibrium was assessed for each SNP.  Known pleiotropy was 
assessed using the phenoscanner database.  Unknown pleiotropy 
was assessed using MR-Egger. Using the IVW approach, the odds of 
CAD was 0.89 lower per one standard deviation of genetically 
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determined higher level of alanine and was statistically 
significant (95% confidence interval (CI) (0.80-0.99). The odds 
of CAD was 1.09 higher per one standard deviation of genetically 
determined higher level of glutamine and was not statistically 
significant (95% confidence interval (CI) (0.99-1.19).  The odds 
of CAD was 0.94 lower per one standard deviation of genetically 
determined higher level of glycine and was statistically 
significant (95% confidence interval (CI) (0.91-0.98). After 
sensitivity analyses suggested pleiotropic effects, the analysis 
was repeated, removing SNPs with known pleiotropy.  Results 
remained the same for all three amino acids.  MI was not 
statistically significantly associated with any of the amino 
acids.   This study provides genetic validation that alanine 
could be a new target of intervention to prevent the leading 
cause of global morbidity and mortality. Glutamine should be 
investigated further to determine its status as a risk factor 
for CAD.  Glycine may decrease the risk of coronary artery 
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Specific Aims   
Aim 1: (Alanine)  
To estimate the causal effect of alanine on coronary artery 
disease (CAD) and myocardial infarction (MI)using instrumental 
variable analysis with a genetic instrument, i.e., Mendelian 
randomization. 
Hypothesis 1:  A genetically higher level of alanine is causally 
associated with a lower risk of CAD. 
Aim 2: (Glutamine)  
To estimate the causal effect of glutamine on CAD/MI using 
instrumental variable analysis with genetic instruments, i.e., 
Mendelian randomization.  
Hypothesis 2: A genetically higher level of glutamine is 
causally associated with a lower risk of CAD and MI. 
Aim 3: (Glycine)  
To estimate the causal effect of glycine on CAD/MI using 
instrumental variable analysis with genetic instruments, i.e., 
Mendelian randomization. 
Hypothesis 3: A genetically higher level of glycine is causally 








Cardiovascular disease (CVD) is the leading cause of death 
worldwide.[1, 2] The World Health Organization (WHO) estimates 
that in 2016, 17,900,00 deaths, or 31% of all deaths, were from 
CVD.[2] In the United States in 2015, about one in four deaths, 
or approximately 610,000 deaths, were due to CVD.[3-5] Coronary 
artery disease (CAD) accounted for 42% of all CVD deaths 
worldwide in 2015, or approximately 7.4 million deaths, while 
CAD accounted for about 60% of all CVD deaths in the United 
States, or approximately 375,000 deaths.[3, 4, 6-11] 
 
Observational epidemiological studies have identified numerous 
risk factors for CAD, including hypertension, hyperlipidemia, 
smoking, obesity, diabetes, unhealthy diet, and physical 
inactivity.[6, 12-21] However, a large proportion of CVD events 
occur in individuals with low predicted-risk based on 
established risk factors.[22] Furthermore, risk stratification 
models predict higher CAD for men than women at the same levels 
of known risk factors.[16-21, 23] Randomized controlled trials 
(RCTs)[24] have identified that pharmacotherapies capable of 
mitigating CAD risk factors and CAD have had inconsistent 
results.[15] How known risk factors and other factors combine to 
cause CAD remains poorly understood,[6, 25-27] and the elements 
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of a healthy diet, including fat, protein, carbohydrates, 
vitamins and minerals have proved difficult to establish, 
begging the question “does diet matter?”[28]   Meta-analyses of 
observational studies do not always draw the same conclusion 
about the relationship between protein consumption and 
CAD/myocardial infarction (MI).[29-32] The building blocks of 
proteins are amino acids, and their relationship with CAD/MI is 
not clearly documented in the literature. The mixed results of 
observational studies provide a justification for exploring the 
relationship of amino acids, such as alanine, glutamine, and 
glycine with CAD/MI.   
Considerable opportunity to identify new casual factors and 
treatments for CAD/MI remain. This study will use Mendelian 
randomization (MR) to estimate the effects of key amino acids on 
CAD/MI. MR has several advantages when compared to conventional 
observational studies and is being increasingly used because it 
overcomes some major limitations of observational study designs, 
including unmeasured confounding. This MR study will lead to a 
better understanding of the causes of CAD/MI. 
 
Observational studies have begun investigating  the relationship 
of amino acids to health and in particular, CAD.[33]  Some of 
these studies have identified amino acids that seem to be 
protective against metabolic diseases such as diabetes or CAD, 
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and others have identified amino acids that are likely risk 
factors for metabolic diseases or CAD. In many cases, it remains 
unclear if biomarkers such as amino acids are merely correlated 
with CAD/MI, or causally related.[28, 34-44]  Moreover, if they 




Glutamine, glycine, and alanine have been established in animal 
studies to be linked with heart function and heart disease.[34-
36, 40-42, 45-48]  Glutamine is commonly found in nuts, which 
observational studies and RCTs have found to be cardio-
protective.[44, 49-51] Animal model and small RCT studies have 
found that glutamine improves postoperative outcomes and 
restores the heart to normal function more quickly than without 
glutamine supplements.[38, 47, 48]  Similarly, glycine studies 
have shown an inverse relationship with CAD and CAD risk factors 
such as hypertension. Alanine studies have shown a paradoxical 
relationship with diabetes, a risk factor for CAD, in light of 
the beneficial role that alanine plays in glucose homeostasis 
and the increased alanine observed during cardiac events.[52-54]   
 
 Glutamine and glycine are conditionally-essential amino 
acids.[39, 40]  This means under normal circumstances the body 
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produces the necessary amount of these amino acids for the 
biosynthesis of proteins.   However, in conditions such as 
injury and stress, the body may supplement these amino acids 
through dietary intake.[37] Glutamine is found in a variety of 
foods, including nuts.[49-51] The most relevant glutamine 
producing human tissue is muscle, accounting for the majority of 
the glutamine produced by the body.[39] Glycine is most notably 
found in gelatin and is a major component of collagen, which is 
abundant in blood vessels and the gut, among other fibrous 
tissues.[36, 40, 42, 55, 56]   
 Glutamine is found in many supplements used by athletes 
because it helps signal cell growth and increases water 
retention in muscle cells.[34] It is commonly found in walnuts 
and other nuts.[51]  An RCT in 2011 assessed the cardio-
protective effects of glutamine on patients with CAD following 
open heart surgery.[38] Clinical tests after surgery found that 
glutamine improved heart functioning in the experimental 
arm.[39] In an animal experiment, researchers reported that 
post-ischemic reperfusion of a rat heart with glutamine restored 
normal cardiac output.[41] A meta-analysis of 53 RCT studies 
found moderate to weak evidence that glutamine supplementation 
would influence outcomes such as infection and recovery from 
surgery and other critical illness.   However, they found no 
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effect on the risk of mortality or length of intensive care unit 
(ICU) stay.[39]   
 
Glycine is an amino acid involved in anti-oxidative reactions 
and collagen formation.[56]   Many observational studies have 
shown an inverse association of glycine with hypertension and 
type two diabetes.[42]  A 2016 RCT assessed the relationship of 
plasma glycine and acute myocardial infarction in patients with 
stable angina. They reported that glycine was inversely 
associated with the risk of MI.[56] They found a stronger 
association in patients with apolipoprotein B, low density 
lipoprotein cholesterol, or apolipoprotein A-1 above the 
median.[56]   Other studies have reported the positive effects 
of glycine on vascular health.[42]  Glycine has been reported to 
stabilize platelets, reduce the size of the ischemia injury upon 
reperfusion, correct elevated blood pressure and normalize serum 
triglycerides.[55, 56] While these studies in rats and humans 
have reported an inverse relationship with glycine and CAD or 
CAD related risk factors, they have not compared glycine levels 
in those with to those without cardiovascular disease.   
  
Alanine is a non-essential amino acid, meaning that the human 
body can produce the amount required and no diet source is 
needed to supplement endogenously produced alanine.  Alanine is 
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found in red meat.  There have been some studies that reported 
an association between the levels of alanine in the urine and 
hypertension, diet, cholesterol, and body mass index (BMI), 
however, these studies have not measured dietary alanine or 
plasma alanine levels.  Another study found that higher serum 
levels of alanine were associated with the development of type 2 
diabetes.[57]  
  
Alanine and glutamine are considered the most important amino 
acids in the blood and are the only amino acids that are taken 
up or released by human skeletal muscle.[36] Once alanine is 
synthesized, it is converted to pyruvate and is critical in 
blood sugar management.[36]  Animal studies have reported that 
heart tissue releases alanine only after a CAD event, otherwise 
the heart only releases alanine under stress.[48, 58] In another 
study, researchers used the Hoorn cohort study data to assess 
the relationship between elevated alanine serum levels and 
actual CAD events at 10-year follow up.[59]  The study found an 
age- and sex-adjusted two-fold increased hazard of experiencing 
a CAD event at the 10-year follow up point. Furthermore, when 
adjusted for the most well-known CAD risk factors, the hazard 
ratio for those with elevated alanine was 1.88, suggesting an 
independent pathway of alanine from the known risk factors. The 
effect of amino acids, such as alanine, on glucose metabolism 
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are well established, however, the net impact on glucose 
homeostasis remains unclear.[54]  The literature contains 
reports of both positive and negative impacts of amino acids on 
glycemic regulation and metabolic syndrome.[54]  Alanine may be 
a marker of an underlying etiology relating to the paradoxical 
association of diabetes with CAD at the population level.  
However, the discrepancy reported in these studies generates 
more questions than answers about the relationship of alanine to 
CAD and in each case, these studies establish an association but 
do not establish a causal relationship.[54] 
 The existing literature suggests inconsistent effects of 
alanine, glycine, and glutamine on CVD and CVD related risk 
factors.  A large RCT with CAD events as the primary outcome 
would be definitive, but costly. Additionally, randomly 
assigning research participants to alter amino acid consumption 
to determine the effect on CAD would be impractical and 
difficult to implement, as modifying diet on a long-term basis 
presents a compliance challenge and the outcome of interest 
takes decades to develop. It would also take several years and 
be difficult to justify with such little evidence of the 
benefits of glutamine and glycine.    
 This difficulty justifies a novel methodological approach 
that assesses the effects of risk factors according to 
genetically determined serum levels of glycine, glutamine, and 
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alanine.  Mendelian randomization (MR) has emerged as a popular 
epidemiological method to obtain unconfounded causal 
estimates.[60-62] 
Methods/Mendelian Randomization 
Epidemiological studies fall into two general categories: 
experimental and observational studies. Experimental studies are 
characterized by the random assignment of the exposure. 
Observational studies can be designed in a variety of ways; 
however, none lend themselves to estimating causal relationships 
unequivocally, because of the risk of selection bias and 
confounding. 
 
In health-related research, the randomized control trial (RCT) 
is the defining experimental study design. In the RCT, study 
participants are randomly assigned to a study arm, receiving one 
of several interventions or no intervention entirely by chance. 
This approach ensures that any measured, and, more importantly, 
unmeasured confounding is equally distributed across the study 
arms, minimizing the risk of spurious or erroneous findings.  
Blinding of all those involved with an RCT further strengthens 
the findings. However, RCTs are time-consuming and expensive. 
Moreover, not all exposures can feasibly be randomized. 
Observational studies may complement some of the limitations of 
RCTs but are not without limitations of their own.  Determining 
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a causal relationship between a risk factor and health outcome 
in observational studies often relies on making some untestable 
and unlikely assumptions, such as no unmeasured confounding and 
no selection bias.  
 
Mendelian randomization (MR) uses genetic variants as 
instrumental variables for modifiable risk factors that affect 
population health.[63] MR utilizes the econometrics method of 
instrumental variable (IV) analysis with genetic variants as the 
IV and offers a novel approach to estimating causal effects from 
observational studies. The principle underlying MR originates 
from the “The Law of Independent Assortment,” also known as 
Mendel’s second law, which states that inheritance of one trait 
is independent of other traits, thus allowing for the use of 
observational data with genetic variants as a natural 
experiment.[63, 64] MR is the use of data from nonexperimental 
studies to determine the causal effect of a phenotype on a 
disease outcome by leveraging the random assignment of genetic 
material at birth. Genetic variants, being fixed at conception, 
support causal inference by minimizing confounding.[63] As the 
knowledge of the human genome has grown, and access to genetic 
data increased, researchers have identified an increasing number 




As of 2015, genome-wide association studies had identified 46 
loci directly linked to CAD, yet a majority of these loci have 
no apparent relation to cholesterol or other classical risk 
factors.[65] Evans and Smith (2015), note that since the formal 
presentation of the MR approach, an increasing number of 
mentions appear in reviews of scientific abstracts of peer-
reviewed publications, with a steeply increasing trajectory.[66] 
  
The first use of the term Mendelian randomization was in 1991 to 
describe a means of obtaining unbiased causal estimates when 
comparing bone marrow transplant with chemotherapy outcomes in 
the treatment of leukemia.[62] The first generation of genome-
wide association Studies (GWAS) were used to show that several 
genetic variants were significantly associated with CAD in 
2007.[67] The MR approach has been used to elucidate causal 
relationships in several areas of observational epidemiology, 
including the causal role of body mass index on blood 
pressure,[68, 69] and in evidence against the causal role of C-
reactive protein in CAD or atherosclerosis.[33, 70-74] MR has 
been used extensively in CAD research, for example, to 
demonstrate that C-reactive protein levels are not causally 
associated with CAD, whereas lipoprotein(a) (Lp[a]) levels are 
causally associated with CAD, and to further our understanding 
of cardiovascular therapies, such as statins.[75, 76]   
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With the increased availability of molecular profiling 
techniques, particular interest has been shown in identifying 
novel biomarkers for cardiovascular or metabolic risk.[33] These 
methods have increased the availability of observational data 
sources that include genetic information to examine different 
exposures using MR to assess causal effects.[26, 62, 66, 76-80] 
This dissertation project will apply MR to publicly available 
data to evaluate the causal effect of three amino acids, 
specifically alanine, glutamine, and glycine, on the risk of CAD 
in adults.[26, 79, 80] 
 
MR is a very powerful technique, but it does have strong 
assumptions that must be met to obtain a valid estimate. The 
assumptions of MR can be most clearly conveyed using a directed 
acyclic graph (DAG). The DAG for MR shows the causal 
relationships between the genetic instrument (Z), the modifiable 
risk factor (X), the outcome (Y) and the (known or unknown, 
measurable or non-measurable) confounders (U), as shown in 



















In an RCT, generally a treatment or other preventive measure is 
randomly assigned and so is not confounded. MR is instrumental 
variable analysis with genetic instruments.[60-62, 66, 77, 78] 
MR is based on the premise of random allocation of alleles at 
time of gamete formation, and hence is thought to be independent 
of confounding factors[60-62, 66, 77, 78, 81-84]. MR 
approximates RCT study design in this respect. However, it is 
important to note that the DAG shown in Figure 1 requires three 
key assumptions to be valid. These assumptions are implicit in 












1) Relevance: The instrumental variables strongly predict the 
exposure 
2) Independence: The instrumental variable is not confounded 
by the confounders of the exposure outcome relation 
3) Exclusion-restriction: The instrumental variable only 




The purpose of this study is to better understand the causal 
relationship of three amino acids: glycine, glutamine and 
alanine with CAD. However, the casual mechanism of the RCT may 
more closely resemble the real-world relationship of the 
exposure with disease than the mechanism evaluated in an MR.   
First, the exposure that is assessed in the MR is a lifelong 
difference between genetic groups, while most RCTs and 
observational studies of CAD/MI are conducted in mature 
individuals.  In this case, canalization, or an individual 
developing a compensatory mechanism in response to prolonged 
higher or lower levels of the exposure, is a possibility.  Also, 
the prolonged exposure time assessed in the MR analysis could 
represent a cumulative effect of the exposure over time, rather 





Second, some diseases are irreversible at a certain point of 
progression.  No RCT or observational study could be designed 
that would be able to replicate the protective effects of 
reducing a harmful exposure that would be a result of genetic 
effects. 
   
The efficacy of acute responses to sudden large increases in a 
harmful exposure cannot be assessed by a MR analysis.  However, 
interest is usually in the lifelong effects of usual levels of 
exposure on disease.  MR is an advantageous approach in this 
regard, as it is not possible to design an RCT that would assess 
lifelong average usual levels of exposure. 
 
Alanine, glutamine and glycine and their relationship to CAD 
have yet to be evaluated using MR, instrumental variable 






Cardiovascular disease (CVD) is the leading cause of death 
worldwide. CVD is poorly understood.  Little attention has been 
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given to the potential cardioprotective effects of alanine in 
humans.  The relationship has primarily been explored in vitro 
and in animal models.  Few observational studies have explored 
the effect of alanine on heart disease.  To clarify we assessed 
whether people with genetically higher levels of alanine had 
lower coronary artery disease (CAD) and myocardial infarction 
(MI) risk. We used a two sample Mendelian randomization study. 
Six SNPs strongly associated (genome wide significant) with 
alanine were applied to large extensively genotyped CAD and MI 
studies to obtain unconfounded estimates.  A one standard 
deviation increased level of alanine was found to protect 
against CAD (odds ratio (OR) 0.89, 95% confidence interval (CI) 
0.80-0.99) but not MI (OR 0.90, 95% CI 0.80-1.02). Sensitivity 
analysis supports these findings.  Our findings are consistent 
with the limited observational evidence, in vitro and animal 
studies.  These findings genetically validate alanine as a 
potential target of intervention in CAD.  Future clinical 
research is needed to better understand the mechanism through 
which alanine influences CAD and to develop effective treatment 








Cardiovascular disease (CVD) is the leading cause of death 
worldwide.[1, 2] The World Health Organization (WHO) estimates 
that in 2016, 17,900,00 deaths, or 31% of all deaths, were from 
CVD.[2] In the United States in 2015, about one in four deaths, 
or approximately 610,000 deaths, were due to CVD.[3-5] Coronary 
artery disease (CAD) accounted for 42% of all CVD deaths 
worldwide in 2015, or approximately 7.4 million deaths, while 
CAD accounted for about 60% of all CVD deaths in the United 
States, or approximately 375,000 deaths.[3, 4, 6-11] 
 
Observational epidemiological studies have identified numerous 
risk factors for CAD, including hypertension, hyperlipidemia, 
smoking, obesity, diabetes, unhealthy diet, and physical 
inactivity.[12-14] Yet, how diet, including protein, causes CAD 
remains poorly understood.[6, 25-27] Meta-analyses of 
observational studies do not always draw the same conclusion 
about the relationship between protein consumption and 
CAD/myocardial infarction (MI).[29-32]  
 
Alanine is a non-essential amino acid, meaning that the human 
body can produce the amount required and that no diet source is 
needed to supplement endogenously produced alanine.[36] Alanine 
can also be obtained from diet, and is found in red meat[85].  
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Alanine levels have been shown to deviate from normal in 
response to cardiac insult, but studies of alanine and CAD have 
not established a clear association.[86] There have been some 
studies that reported associations between levels of alanine in 
the urine and hypertension, diet, cholesterol and body mass 
index (BMI); however, these studies did not measure dietary 
alanine or plasma alanine levels.[45, 87] Some studies have 
found that higher serum levels of alanine may protect against 
CAD.[52-54] Other studies have shown that increased levels of 
alanine are associated with CAD and other CVD.[88-91] However 
higher levels of alanine appear to mitigate some type 2 diabetes 
symptoms, in particular by activating an adenosine monophosphate 
(AMP)-activated protein kinase nutrient sensor.[88] Alanine may 
be a marker of an underlying etiology explaining the paradoxical 
association of diabetes with CAD at the population level.[54] 
However, the inconsistencies reported in these studies have 
generated more questions than answers about the relationship of 
alanine to CAD, and in each case, these studies established an 
association but did not establish a causal relationship.[54] 
 
There remains a considerable opportunity to identify new casual 
factors and treatments for CAD/MI. This study will use Mendelian 
randomization (MR) to estimate the effects of alanine on CAD/MI. 
MR has several advantages when compared to conventional 
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observational studies and is being increasingly used because it 
overcomes some major limitations of observational study designs, 
including unmeasured confounding. MR uses genetic variants as 
instrumental variables for modifiable risk factors that affect 
population health.[63] The principle underlying MR originates 
from the “The Law of Independent Assortment,” also known as 
Mendel’s second law, which states that inheritance of one trait 
is independent of other traits, thus allowing use of 
observational data with genetic variants as natural 
experiments.[63, 64] Genetic variants, being fixed at 





MR depends on three assumptions.  The relevance, independence 
and exclusion restriction assumptions are key in selecting valid 
instrumental variables.  The relevance assumption means that the 
genetic instruments predict the exposure reliably. The relevance 
assumption is assured by selecting single nucleotide 
polymorphisms (SNPs) strongly associated with the exposure of 
interest, ideally at genome wide significance, from genome-wide 
association studies (GWAS).[63] The independence assumption 
means that the genetic instruments are not associated with 
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confounders of the exposure outcome relation. The independence 
assumption requires that potential confounders of the exposure 
outcome relation do not confound the genetic variant outcome 
relation, to minimize the possibility of confounding.[63, 92] 
The exclusion-restriction assumption means that the genetic 
instruments are only associated with the outcome via the 
exposure. The exclusion restriction assumption is assessed from 
biological knowledge of the effects of the genetic instruments, 
known associations of the genetic instruments with other factors 
and statistical tests for pleiotropy. 
Contributed data was corrected for population stratification, 
which has been shown to occur even in single ethnicity 
populations. Ancestry and the non-random distribution of SNPs 
was corrected for using genomic control by adjusting for 
principal components. 
 
Genetic associations with alanine 
Genetically determined levels of alanine were obtained from a 
GWAS.[93, 94] The Computational Medicine extended GWAS combined 
data from 11 genetic studies and 14 data sources for a total 
sample size of 24,925 individuals of European descent (Finland, 
Estonian, Netherlands and Germany).[93, 94] The mean age of the 
study participants was 44.6 years. The individual study average 
ages ranged from 31.2 to 61.3 years. Women were 55% of the total 
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sample, and individual study samples ranged from 37% to 64% 
female.[93, 94] SNPs strongly and independently associated with 
alanine (p<5x10-8) were selected.[93, 94] The MR-Base “clumping” 
function was used to identify correlations between the chosen 
SNPs,[95] and only uncorrelated SNPs were retained (r2<0.001). 
SNP effects on CAD/MI via physiologic pathways other than 
alanine (pleiotropy) were assessed from a comprehensive genotype 
to phenotype cross-reference, PhenoScanner.[96, 97]   
 
 
Genetic associations with CAD and MI 
Data on coronary artery disease / myocardial infarction have 
been contributed by the CARDIoGRAMplusC4D. Data have been 
downloaded from www.CARDIOGRAMPLUSC4D.ORG. CARDIoGRAMplusC4D 
1000 Genomes is a CAD and MI case (n=60,801)-control (n=123,504) 
study, extensively genotyped using the 1000 Genomes catalog. The 
majority (77%) of the participants were of European ancestry; 
13% and 6% were of South Asian (India and Pakistan) and East 
Asian (China and Korea) ancestry, respectively, with smaller 
samples of Hispanic and African Americans. The mean age was 
about 56.9 years, with genetic associations adjusted for study 
specific covariates. Phenotyping of CAD, MI or both, were based 
on medical records, clinical diagnosis, procedures that indicate 
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Associations of alanine with CAD/MI were obtained from separate 
sample instrumental variable analysis with genetic instruments.  
SNP-specific Wald estimates (ratio of SNP on CAD/MI to SNP on 
alanine) of the effect of alanine on CAD/MI were obtained. The 
confidence interval for the Wald estimates were obtained using 
an approximation to Fieller’s theorem[66, 98-101].[102]  
 
The SNP specific Wald-estimates were combined using inverse-
variance  weighting (IVW) with multiplicative random 
effects.[103] The IVW approach is asymptotically equivalent to 
the two-stage least squares (2SLS) estimate commonly used with 
individual-level data and yields comparable causal 
estimates.[104, 105]  
 
SNPs were aligned on effect allele, and direction of effect 
amended accordingly using allele harmonization.  There were no 
palindromic SNPs.  All six SNPs for alanine were available for 






For sensitivity analysis, I used weighted median and MR-Egger 
regression.[104] The weighted-median is robust even in the event 
of some violations to the IV assumptions. This method provides a 
consistent estimate if at least 50% of the weight comes from 
valid IVs.[104] In simulation studies, the weighted-median 
estimation method produces similar point estimates, narrower 
confidence intervals and better finite-sample Type 1 error rates 
than IVW and the 2SLS method.[104]  
 
The MR-Egger method uses a different, still untestable set of 
assumptions.[104] MR-Egger regression performs well even when 
100% of the IVs are invalid.[104] The slope coefficient from the 
Egger regression method provides an estimate of the causal 
effect that is consistent asymptotically even if all the genetic 
variants have pleiotropic effects on the outcome; but assumes 
the inSiDe assumption— (instrument strength independent of 
direct effect). A stronger genetic variant should have more 
reliable estimates of the causal effect than a weaker variant. 
Once the average pleiotropic effect of variants is accounted for 
through the intercept term in Egger regression, any residual 
dose–response relationship in the genetic associations provides 
evidence of a causal effect. A non-null intercept from MR-Egger 




Analysis was conducted using the TwoSample MR package version 
0.4.14 for R software version 3.5.1, available at 
https://github.com/MRCIEU/TwoSampleMR. Analysis was verified 
using the MR-base platform version 1.2.1 e646be (05 December 
2018), available at http://app.mrbase.org/. This analysis of 
publicly available data did not require IRB approval. 
 
Results 
Genetic determinants of alanine 
One hundred and twenty-six SNPs were identified from GWAS with 
p<1x10-5. Of these, 120 SNPs were excluded because they did not 
reach genome wide significance (p<5x10-8). Of the remaining six 
SNPs, none were in linkage disequilibrium (R2<0.001). The F-
statistic for SNPs included in the CAD and MI analyses was 56.92 
and SNP specific F-statistic ranged from 36.79 to 110.70.[106-
108]  No palindromic SNPs were included in this analysis, and 
all SNPs in the SNP exposure dataset were available in the 
outcome dataset, for additional information about the included 
SNPs see table 2 in the appendix.  
In MR studies obtaining adequate statistical power is frequently 
a concern due to the small amount of variation in a phenotypic 
trait that is typically explained by genetic variants, which is 
addressed by using large samples for the outcome. To achieve the 
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widely accepted power of 80% for epidemiological studies a 
sample of about 255,000 participants would be needed for CAD and 
about 326,553 participants would be needed for MI.[106-108] The 
power calculated for these analyses was .66 for CAD with 184,000 
participants and .52 for MI with 171,000 participants.[106-108] 
 
Association of genetically determined alanine with CAD risk 
Table 1 shows that the unconfounded estimate of one standard 
deviation (SD) higher genetically determined alanine was 
associated with lower risk for CAD. Using the IVW approach, the 
odds of CAD was 0.89 lower among those with genetically 
determined higher levels of alanine than those with lower 
genetically determined alanine and was statistically significant 
(95% confidence interval (CI) (0.80-0.99). Sensitivity analysis 
results obtained using the weighted median and MR-Egger 
regression method were not statistically significant, but were 
similar in direction, as shown in table 1 and figure 1.  Figure 
1 shows the Wald estimates for included SNPs individually, as 
well as the MR-Egger and IVW regression results for all SNPs 
combined. All but one SNP (rs12578760) was found to be 
associated with a lower risk of CAD.  The funnel plot in figure 
4 does not indicate heterogeneity among the SNPs, however, the 





Association of genetically determined alanine with MI risk 
Table 1 shows that the causal effect of one standard deviation 
(SD) higher genetically determined alanine was not associated 
with MI. Using the IVW approach, the odds of MI was 0.90 lower 
among per SD of alanine (95% CI (0.800-1.015). Sensitivity 
analysis results obtained using the weighted median and MR-Egger 
regression method were not statistically significant, but were 
directionally similar, as shown in table 1 and figure 1.  Figure 
1 shows the Wald estimate for included SNPs individually, as 
well as the MR-Egger and IVW regression results for all SNPs 
combined. All but one SNP were found to be associated with lower  
MI.  The funnel plot in figure 4 does not indicate heterogeneity 
among the SNPs, however, the lack of symmetry could be an 
indication that an invalid SNP was included. 











Figure 1 – Wald ratio for individual SNPs and MR-Egger and IVW 
















Table 1 MR estimates of the associations of log-transformed 

















IVW 0.889 0.795-0.993 0.369 - 
Weighted 
Median 
0.928 0.807-1.066 - - 
MR-Egger 0.875 0.486-1.578 0.249 0.961 
MI 6 
IVW 0.901 0.800-1.015 0.763 - 
Weighted 
Median 
0.929 0.801-1.076 - - 
MR-Egger 0.932 0.530-1.637 0.631 0.911 
 
One SNP, rs1260326 was associated with cholesterol and 
triglyceride levels, fasting glucose and blood pressure.  The 
remaining SNPs had either no known pleiotropic effects or were 
associated with factors not associated with heart disease, such 
as glaucoma. Table 3 in the appendix shows these relations. 
Estimates were similar after excluding rs1260326.  The IVW 
estimate remained statistically significant (odds ratio (OR) – 
0.848, 95% confidence interval (CI) 0.742-0.969 and the MR-Egger 
results were (OR-0.641, 95% CI 0.321-1.281.  The intercept P-








This novel study provides unconfounded estimates that alanine is 
associated with a lower risk of CAD. Clinical studies have found 
that perfusing the heart with alanine after surgery has improved 
recovery, and decreased risk of post-operative infection.[89, 
90, 109, 110] Furthermore, small studies conducted in athletes 
have shown alanine supplementation has led to improved sports 
and exercise performance.[52, 53].  This study provides genetic 
validation for alanine as a new target of intervention in CAD. 
 
This study has the advantage of using a novel technique which 
enables estimates to be made cost-effectively even when no study 
including both the exposure and outcome is available. It also 
has the advantage of providing unconfounded estimates.  However, 
MR has stringent assumptions. First, the relevance assumption 
requires that SNPs be strongly associated with the exposure of 
interest.[63]  This study used SNPs that were associated with 
the exposure at a P-value <5 x10-8.  Second, the independence 
assumption requires that SNPs be independent of exposure outcome 
confounders.  This would be expected, as genetic makeup is 
determined a conception and independently from each other.[64] 
Third, the exclusion-restriction assumption requires that the 
SNP affects the outcome only via its effect on the risk factor 
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of interest.[63] Known pleiotropy was assessed using 
phennoscanner and few associations with known CAD/MI risk 
factors were found for the SNPs included in this analysis.[96, 
97] However, estimates were similar after pleiotropic SNPs were 
excluded.  Unknown pleiotropy was evaluated using MR-Egger 
intercept, and found no indication of pleiotropy.  Given the use 
of summarized data in two samples, serum alanine levels were not 
measured in the sample with the outcome. However, two-sample 
instrumental variable analysis is more robust to chance 
associations than analysis of a single sample.[26] Despite the 
advantages of MR analysis, several limitations warrant mention.   
 
Making inferences from population based genetic studies, one 
would be concerned with population stratification; when a 
population subgroup experiences different disease and SNP 
frequencies resulting in confounded associations in a whole 
population study. The exposure and outcome data included people 
largely of European descent.  While this study can no assess the 
effect of alanine on CAD/MI by subgroup, there is no reason to 
think that mechanism by which alanine affects CAD/MI is group 
specific.  Canalization, or developmental compensation occurs 
when molecular mechanisms compensate for the effect of the 
genotype of interest on the outcome of interest.   
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Weak instrument bias should not influence results of this study.  
All included SNPs reach genome wide significance.  However, a 
weak instrument would bias results toward the null.  Non-linear 
effects have successfully been identified using MR, but depend 
on additional assumptions.  I had to assume a linear 
relationship.  Participant overlap may have occurred in this two 
sample MR analysis.  However, given the very large sample size 
of the exposure and outcome datasets, the bias if any should not 
be of major concern. The CAD/MI case-control studies included 
are not wholly composed of incident cases.  Therefore 
associations may represent survival with CAD and of a MI rather 
than prevention of these outcomes. Finally, MR is better at 
identifying the direction of effect rather than its magnitude, 
though, the entire population is exposed to alanine, making any 
effect relevant to population health.   
 
Alanine might protect against CAD. In rats, introducing alanine 
in their diets consistently activated the adenosine 
monophosphate-activated protein kinase (AMPK) enzyme.[88]  AMPK 
is an enzyme found in the body that is activated when nutrients 
are low and during exercise.[88] This study also found that in 
rat, mouse and human cells introduction of alanine reduced 
glucose levels, not via increases of insulin secretion rather 
via increased glucose uptake in the liver.[88] 
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Chronic beta-alanine supplementation increases muscle carnosine 
concentration, subsequently leading to an improved performance 
in high-intensity exercise.[52] The mechanisms by which enhanced 
muscle carnosine concentrations result in improved exercise 
performance need to be refined in detail, with particular focus 
on a complex interaction between pH buffering and improved Ca2+ 
handling.[52] Observational studies and MR studies have clearly 
established the positive relationship between calcium and 
CAD.[26, 52, 111, 112]   
 
Since the 1980’s the peer-reviewed literature has supported the 
potential for alanine to influence some mechanisms related to 
CAD and CAD risk factors.[113] The majority of studies exploring 
this relationship have been explored in vitro and in animal 
studies.[113]  The paucity of population-based peer-reviewed 
literature addressing the relationship of alanine with human CAD 
suggests little consideration has been given to the relationship 
in epidemiological literature.  Alanine is found abundantly in 
the musculoskeletal and heart cells.[85, 88, 90, 91, 113-116]   
Furthermore, beta-alanine is known to increase muscle carnosine 
levels.[35, 36, 52, 53, 85, 113, 116] Observational studies 
among athletes have shown that beta-alanine supplementation 
improves exercise performance.[52, 53, 113] Carnosine is widely 
considered an important anti-glycating agent, potentially 
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improving energy metabolism and protein homeostasis.[113]  
Improved handling of glycation end products has had promising 
results with diabetes complications, a CAD risk factor.[113] 
Additionally, carnosine has antioxidative properties, which are 
thought to improve heart health.[90, 113]  However, little data 
exists regarding alanine promoting antioxidative processes via 
carnosine.  Therefore, future research evaluating its 
antioxidative potential in humans is warranted. Observational 
studies in the early 2000’s energized interest in antioxidants 
processes and heart disease.[89, 110, 113]  Subsequent RCTs 
concluded that there was little or no benefit of antioxidant 
supplementation in reducing cardiovascular risk. It is possible 
that the wrong antioxidants or combination of antioxidants, such 
as α-tocopherol and β-carotene have been researched.[113, 116] 
Other reasons for the failure of these RCTs to confirm the 
observational findings are incorrect dosage, synthetic 
antioxidants rather than dietary source and selection bias.[113, 
116]    
 
Conclusion 
This study provides genetic validation that alanine could be a 
new target of intervention to prevent the leading cause of 
global morbidity and mortality. Alanine can be modified by diet 
changes as it is found in red meat and poultry or via dietary 
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supplements.  The effects and mechanisms by which beta alanine 
impacts health should be further evaluated in experimental and 
clinical studies, beyond the existing literature of in vitro and 
animal studies.   
 
Appendix 
Table 2 Characteristics of the single nucleotide polymorphisms 
























C T 0.07967 0.01314 0.8539 <0.001 
rs1260326 GCKR C T -0.10458 0.00994 0.5895 <0.001 
rs149191093 DDX19B C T 
-
0.161931 
0.024508 0.9632 <0.001 
rs2160387 - T C 
-
0.071001 
0.009603 0.5567 <0.001 
rs2694917 RBMS2 C T 0.086007 0.012989 0.2266 <0.001 
rs4554975 SLC38A4 A G 
-
0.069135 
0.009598 0.4294 <0.001 
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Table 3 Select Pleiotropic effects of Relevant Alanine SNPs  
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Figure 4 - Funnel plot of Relevant SNPs  to assess heterogeneity 
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Cardiovascular disease (CVD) is the leading cause of death 
worldwide. The strong relationship between CVD and lipids has 
been well documented in the peer reviewed literature. Little 
attention has been given to other, smaller molecular level 
dietary components.  Glutamine, a non-essential amino acid and 
its effect on Coronary Artery Disease (CAD) have been studied in 
animal, observational, in vitro and RCT studies.  These studies 
have had mixed findings raising doubt as to the protective 
effect of glutamine on CAD/MI.   To clarify we assessed whether 
people with genetically higher levels of glutamine had lower 
coronary artery disease (CAD) and myocardial infarction (MI) 
risk. We used a two sample Mendelian randomization study. five 
SNPs strongly associated (genome wide significant) with 
glutamine were applied to large extensively genotyped CAD and MI 
studies to obtain unconfounded estimates.  A one standard 
deviation increased level of glutamine was not statistically 
significantly associated with  CAD (OR 1.09, 95% CI 0.99-1.19) 
or MI (OR 1.05, 95% CI 0.95-1.16). The sensitivity analysis also 
indicated that the IVW estimate might be invalid because the p-
value for the MR-Egger intercept was significant. After removing 
pleiotropic SNPs the MR-Egger intercept was no longer 
significant.   Our findings are inconsistent with the 
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observational, in vitro and animal studies findings in the older 
existing literature. However, more recently, observational 
studies have reported glutamine has atherogenic properties and 
two randomized studies found no association between glutamine 
and critical illness. These findings raise new questions of the 
causal effect of glutamine on CAD/MI.  A harmful effect of 
glutamine on CAD cannot be ruled out, future research is needed 




Cardiovascular disease (CVD) is the leading cause of death 
worldwide.[1, 2] The World Health Organization (WHO) estimates 
that in 2016, 17,900,00 deaths, or 31% of all deaths, were from 
CVD.[2] In the United States, about one in four deaths, or 
approximately 610,000 deaths, were due to CVDs.[3-5] Coronary 
artery disease (CAD) accounted for 42% of all CVD deaths 
worldwide, or approximately 7.4 million deaths, while CAD 
accounted for about 60% of all CVD deaths in the United States, 
or approximately 375,000 deaths.[3, 4, 6-11] 
 
Observational epidemiological studies have identified numerous 
risk factors for CAD, including hypertension, hyperlipidemia, 
smoking, obesity, diabetes, unhealthy diet, and physical 
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inactivity.[12-14] Yet, how these and other  factors combine in 
complex causal mechanisms to cause CAD remains poorly 
understood.[6, 25-27] Meta-analyses of observational studies do 
not always draw the same conclusion about the relationship 
between protein consumption and CAD/myocardial infarction 
(MI).[29-32] Furthermore, randomized controlled trials 
(RCTs)[24] that have identified pharmacotherapies capable of 
mitigating CAD risk factors and CAD have had inconsistent 
results.[15] 
 
Glutamine is a conditionally-essential amino acid.[39, 40] This 
means that under normal circumstances, the body produces the 
necessary amount of this amino acid for the biosynthesis of 
proteins. However, in conditions such as injury and stress, the 
body may require supplementation of the amino acid through 
dietary intake.[37] Glutamine is found in a variety of foods, 
notably nuts.[49-51] It is commonly found in walnuts and other 
nuts.[51] The most prominent glutamine-producing human tissue is 
muscle, accounting for the majority of the glutamine produced by 
the body.[39] 
  
Glutamine is found in many supplements used by athletes because 
it helps signal cell growth and increases water retention in 
muscle cells.[34] A 2011 RCT assessed the cardio-protective 
 
 3 
effects of glutamine on patients with CAD following open-heart 
surgery.[38] Clinical tests after surgery found that glutamine 
improved heart function in the experimental arm.[39] In an 
animal trial, researchers reported that post-ischemic 
reperfusion of a rat heart with glutamine restored normal 
cardiac output.[41] A meta-analysis of 53 RCT studies found 
moderate to weak evidence that glutamine supplementation 
influences outcomes such as infection and recovery from surgery 
and other critical illness. However, it found no effect on the 
risk of mortality or length of ICU stay.[39] 
 
The existing literature suggests that glutamine has inconsistent 
effects on CVD and CVD-related risk factors. A large RCT with 
CAD events as the primary outcome would be definitive, but 
costly. Additionally, randomly assigning research participants 
to alter amino acid consumption to determine the effect on CAD 
would be impractical and difficult to implement, as modifying 
diet on a long-term basis presents a compliance challenge, and 
the outcome of interest takes decades to develop. It would also 
take several years and be difficult to justify with such mixed 
evidence of the benefits of glutamine. The potential harmful 




There remains a considerable opportunity to identify new casual 
factors and treatments for CAD/MI. This study will use Mendelian 
randomization (MR) to estimate the effects of glutamine on 
CAD/MI. MR has several advantages when compared to conventional 
observational studies and is being increasingly used because it 
overcomes some major limitations of observational study designs, 
including unmeasured confounding. MR uses genetic variants as 
instrumental variables for modifiable risk factors that affect 
population health.[63] The principle underlying MR originates 
from the “The Law of Independent Assortment,” also known as 
Mendel’s second law, which states that inheritance of one trait 
is independent of other traits, thus allowing for the use of 
observational data with genetic variants as natural 
experiments.[63, 64] Genetic variants, being fixed at 
conception, support causal inference by minimizing 
confounding.[63] MR studies are not influenced by confounding 




As is the case in all analytic approaches, MR depends on three 
assumptions.  The relevance, independence and exclusion 
restriction assumptions are key in selecting valid instrumental 
variables.  The relevance assumption means that the genetic 
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instruments predict the exposure reliably. The relevance 
assumption is assured by selecting single nucleotide 
polymorphisms (SNPs) strongly associated with the exposure of 
interest from genome-wide association studies (GWAS).[63] The 
independence assumption means that the genetic instruments are 
not associated with confounders of the exposure outcome 
relation. The independence assumption requires the assessment of 
SNP effects, to minimize the possibility of confounding.[63, 92] 
The exclusion-restriction assumption means that the genetic 
instruments are only associated with the outcome via the 
exposure. The exclusion restriction assumption is assessed from 
biological knowledge of the effects of the genetic instruments, 
known associations of the genetic instruments with other factors 
and statistical tests for pleiotropy. 
Contributed data was corrected for population stratification, 
which has been shown to occur even in single ethnicity 
populations. Ancestry and the non-random distribution of SNPs 
was corrected for using genomic control by adjusting for 
principal components. 
 
Genetic associations with glutamine 
Genetically determined levels of glutamine were obtained from a 
genome-wide association study (GWAS).[93, 94] The Computational 
Medicine extended GWAS combined data from 11 genetic studies and 
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14 data sources for a total sample size of 24,925 individuals of 
European descent (Finland, Estonian, Netherlands and 
Germany).[93, 94] The mean age of the study participants was 
44.6 years. The individual study average ages ranged from 31.2 
to 61.3 years. Women were 55% of the total sample, and 
individual study samples ranged from 37% to 64% female.[93, 94] 
Single nucleotide polymorphisms (SNPs) strongly and 
independently associated with glutamine (p<5x10-8) were 
selected.[93, 94] The MR-Base “clumping” function was used to 
identify correlations between the chosen SNPs.[95] SNP effects 
on CAD/MI via physiologic pathways other than glutamine 
(pleiotropy) were assessed from a comprehensive genotype and 
phenotype cross-references, PhenoScanner.[96, 97] 
 
Genetic associations with CAD 
Data on CAD/MI were contributed by the CARDIoGRAMplusC4D. Data 
were downloaded from www.CARDIOGRAMPLUSC4D.ORG. 
CARDIoGRAMplusC4D 1000 Genomes is a CAD and MI case (n=60,801)-
control (n=123,504) study extensively genotyped using the 1000 
Genomes catalog that partially overlaps with CARDIoGRAMplusC4D. 
The majority (77%) of the participants were of European 
ancestry; 13% and 6% were of South Asian (India and Pakistan) 
and East Asian (China and Korea) ancestry, respectively, with 
smaller samples of Hispanic and African Americans.  The mean age 
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was about 56.9 years, with genetic associations adjusted for 
study specific covariates. Phenotyping of CAD, MI or both was 
based on medical records, clinical diagnosis, procedures that 
indicate CAD, medications or symptoms that indicate angina, or 
self-reporting of CAD. 
 
Statistical analysis 
Associations of glutamine with CAD/MI were obtained from 
separate sample instrumental variable analysis with genetic 
instruments. SNP-specific Wald estimates (ratio of SNP on CAD/MI 
to SNP on glutamine) of the effect of glutamine on CAD/MI were 
obtained. The confidence intervals for the Wald estimates were 
obtained using an approximation to Fieller’s theorem.[66, 98-
102] 
 
The SNP specific Wald-estimates were combined using inverse-
variance weighting (IVW) with multiplicative random 
effects.[103] The IVW approach is asymptotically equivalent to 
the two-stage least squares (2SLS) estimate commonly used with 
individual-level data and yields comparable causal 







For sensitivity analysis, I used weighted median and MR-Egger 
regression.[104] The weighted-median is a robust alternative 
even in the event of some violations to the IV assumptions. 
Assuming that no single SNP contributes more than 50% of the 
weight to the estimate, this method provides a consistent 
estimate if at least 50% of the weight comes from valid 
IVs.[104] In simulation studies, the weighted-median estimation 
method produces similar point estimates, narrower confidence 
intervals and better finite-sample Type 1 error rates than IVW 
and the 2SLS method.[104]  
 
The MR-Egger method uses a different, still untestable set of 
assumptions.[104] MR-Egger regression performs well even when 
100% of the IVs are invalid.[104] The slope coefficient from the 
Egger regression method provides an estimate of the causal 
effect that is consistent asymptotically even if all the genetic 
variants have pleiotropic effects on the outcome; this is known 
as the inSiDe assumption—instrument strength independent of 
direct effect. A stronger genetic variant should have more 
reliable estimates of the causal effect than a weaker variant. 
Once the average pleiotropic effect of variants is accounted for 
through the intercept term in Egger regression, any residual 
dose–response relationship in the genetic associations provides 
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evidence of a causal effect. A non-null intercept from MR-Egger 
indicates an invalid IVW estimate.  
 
Analysis was conducted using the TwoSample MR package version 
0.4.14 for R software version 3.5.1, available at 
https://github.com/MRCIEU/TwoSampleMR. Analysis was verified 
using the MR-base platform version 1.2.1 e646be (05 December 
2018), available at http://app.mrbase.org/. This analysis of 




Genetic determinants of Glutamine 
Forty-four SNPs were identified from GWAS with p<1x10-5. Of 
these, 38 SNPs were excluded because they did not reach genome 
wide significance (p<5x10-8 ). We attempted to align one 
palindromic SNP, rs7952320 using a minor allele frequency (MAF) 
of 0.3 but the results were ambiguous.  No proxy SNP was 
available and rs7952320 was excluded for both the CAD and MI 
analysis. Of the remaining five SNPs, all were available in the 
outcome dataset.   The final analysis was limited to the 5 SNPs 
available in both datasets. No SNP was in linkage disequilibrium 
(R2<0.001). The F-statistic for SNPs included in the CAD and MI 
analyses was 91.48 and SNP specific F-statistic ranged from 
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31.33 to 314.03.[106-108]For additional information about the 
included SNPs see table 2 in the appendix.   
In MR studies obtaining adequate statistical power is frequently 
a concern due to the small amount of variation in a phenotypic 
trait that is typically explained by genetic variants, which is 
addressed by using large samples for the outcome. To achieve the 
widely accepted power of 80% for epidemiological studies a 
sample of about 194,406 participants would be needed for CAD and 
about 879,248 participants would be needed for MI.[106-108] The 
power calculated for these analyses was .78 for CAD with 184,000 
participants and .23 for MI with 171,000 participants.[106-108] 
 
Association of genetically determined glutamine with CAD risk 
Table 1 shows the unconfounded estimate of one standard 
deviation (SD) higher genetically determined glutamine was not 
clearly associated with increased risk for CAD or MI. Using the 
IVW approach, the odds of CAD was 1.09 higher per 1 SD increase 
in glutamine but was not statistically significant 95% 
confidence interval (CI) (0.99-1.19). Sensitivity analysis 
results obtained using the weighted median and MR-Egger 
regression method were statistically significant, with a similar 
odds ratio estimate as the IVW method, as shown in table 1 and 
figure 1. The sensitivity analysis also indicated that the IVW 
estimate might be invalid because the p-value for the MR-Egger 
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intercept was significant. Figure 1 shows the Wald ratio for 
included SNPs individually, as well as the MR-Egger and IVW 
regression results for all SNPs combined.  The funnel plot in 
figure 4 does not indicate heterogeneity among the SNPs, 
however, because so few SNPs are included symmetry is difficult 
to assess and an invalid SNP may have been included.  The MR-
Egger method is valid even when invalid SNPs are included. The 
findings are unclear and do not unequivocally suggest that 
genetically determined glutamine is associated with increased 
risk of CAD/MI.   
 
Association of genetically determined glutamine with MI risk 
Table 1 shows the unconfounded estimate of one standard 
deviation (SD) higher genetically determined glutamine was not 
associated with increased risk of MI. Using the IVW approach, 
the odds of MI were 1.05 higher among those with genetically 
determined higher levels of glutamine than those with lower 
genetically determined glutamine, and was not statistically 
significant 95% CI (0.95-1.16); however, sensitivity analysis 
results obtained using the MR-Egger regression method was 
statistically significant, and showed increased risk of MI for 
genetically determined higher glutamine levels, as shown in 
table 1 and figure 1.  MR-Egger also suggested that the IVW 
estimate was not valid. Figure 1 shows the Wald ratio for 
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included SNPs individually, as well as the MR-Egger and IVW 
regression results for all SNPs combined. The funnel plot in 
figure 4 does not indicate heterogeneity among the SNPs, 
however, the lack of symmetry could be an indication that an 
invalid SNP was included.  The MR-Egger method is valid even 
when invalid SNPs are included and the findings among all three 
MR methods suggest that the possibility that genetically higher 


















Figure 1 Wald ratio for individual SNPs and MR-Egger and IVW for 
















Table 1 MR estimates of the associations of log-transformed 
















































Two SNPs, rs1260326 and rs6729711 were associated with 
cholesterol and triglyceride levels, fasting glucose and blood 
pressure.  The remaining SNPs had either no known pleiotropic 
effects or were associated with factors not associated with 
heart disease, such as glaucoma. Table 3 in the appendix shows 
these relations. Estimates were similar after excluding 
rs1260326 and rs6729711.  The IVW estimate CAD was (OR – 1.103, 
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95% CI 0.989-1.231) and the MR-Egger results were (OR- 1.254, 
95% CI 1.019-1.543.  The intercept P-value was 0.401 and the Q-
statistic P-value was 0.4602.    
 
Discussion 
This novel study does not exclude the possibility that 
genetically determined glutamine is associated with an increased 
risk of CAD and MI.  The existing literature remains divided on 
the direction of effect that glutamine has on CAD.   Research 
has suggested supplementing glutamine in critically ill patients 
and after surgery reduces infections and mortality rates.[39]  
Clinical studies have found that perfusing the heart with 
glutamine after surgery has improved recovery, and decreased 
risk of post-operative infection.[89, 90, 109, 110] Animal 
models have shown that glutamine, but not glutamate or aspartate 
improved the cardiac output of rat hearts.[41]  The same study 
reported that in a small sample, a single oral dose of glutamine 
improved cardiac function on patients with stable angina.[41] 
Another study linked glutamine supplements to improved immune 
and gastrointestinal function.[37] RCTs have demonstrated that 
glutamine supplements improve outcomes in critically ill 
patients, including one study that found glutamine was 
cardioprotective following cardiopulmonary bypass.[38]  Some RCT 
studies have not found that glutamine has any beneficial effects 
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in critically ill patients.[39, 117, 118] Our study does not 
clearly suggest that glutamine is a risk factor for CAD and MI. 
 
This study has the advantage of using a novel technique which 
enables estimates to be made cost-effectively even when no study 
including both the exposure and outcome is available. It also 
has the advantage of providing unconfounded estimates.  However, 
MR has stringent assumptions. First, the relevance assumption 
requires that SNPs be strongly associated with the exposure of 
interest.[63]  This study used SNPs that were associated with 
the exposure at a P-value <5 x10-8.  Second, the independence 
assumption requires that SNPs be independent of exposure outcome 
confounders.  This would be expected, as genetic makeup is 
determined a conception and independently from each other.[64] 
Third, the exclusion-restriction assumption requires that the 
SNP affects the outcome only via its effect on the risk factor 
of interest.[63] Known pleiotropy was assessed using 
phennoscanner and few associations with known CAD/MI risk 
factors were found for the SNPs included in this analysis.[96, 
97] two SNPs, rs1260326  and rs6729711 are known to also be 
associated with cholesterol and triglyceride levels, fasting 
glucose and blood pressure.  The remaining SNPs had either no 
known pleiotropic effects or were associated with factors not 
associated with heart disease, such as hypothyroidism. For 
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additional information please see the table 3 in the appendix.  
Given the use of summarized data in two samples, serum glutamine 
levels were not measured in the sample with the outcome. 
However, two-sample instrumental variable analysis is more 




Making inferences from population based genetic studies, one 
would be concerned with population stratification[83]; when a 
population subgroup experiences different disease and SNP 
frequencies resulting in confounded associations in a whole 
population study. The exposure and outcome data included people 
largely of European descent.  While this study cannot assess the 
effect of glutamine on CAD/MI by subgroup, there is no reason to 
think that mechanism by which glutamine affects CAD/MI are group 
specific.  Canalization, or developmental compensation occurs 
when molecular mechanisms compensate for the effect of the 
genotype of interest on the outcome of interest.[83]   
Weak instrument bias should not influence results of this 
study.[83]  All included SNPs reach genome wide significance.  
However, a weak instrument would bias results toward the 
null.[119]  Non-linear effects have successfully been identified 
using MR, but depend on additional assumptions.  I had to assume 
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a linear relationship in this analysis.  Participant overlap may 
have occurred in this two sample MR analysis.  However, given 
the very large sample size of the exposure and outcome datasets, 
the bias if any should not be of major concern.[26, 120, 121] 
Finally, MR is better at identifying the direction of effect 
rather than its magnitude, though, the entire population is 
exposed to glutamine, making any effect relevant to population 
health.  
The role of glutamine in CAD and MI remains unclear.  Studies 
have found glutamine a reliable discriminator of CAD and non-CAD 
among cardiac catheterization patients.[114, 122] Glutamine has 
also been found to be associated with plaque development and 
intima–media thickness.[114, 115, 123] Some in vitro and animal 
studies have found that glutamine levels have been associated 
with atherosclerosis and CAD risk. [114]  Glutamine stimulates 
the accumulation of triglycerides  in microphages by affecting 
the SREBP-1, a key regulator in cellular triglyceride 
biosynthesis.[114] Furthermore, glutamine stimulates microphage 
oxidative stress, affecting lipid metabolism.[114]     
 
Conclusion 
This study found glutamine had no statistically significant 
relationship with CAD or MI. It is possible that a study with 
higher power would have detected a small increased risk of CAD 
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and MI in individuals with genetically determined higher 
glutamine.   Glutamine can be modified by diet changes as it is 
found in nuts and red meat or via dietary supplements. The 
literature has hypothesized several biological mechanisms by 
which glutamine effects CAD and MI.  The effect on CAD should be 
conclusively evaluated in a larger MR study to assess glutamine 




Table 2 Characteristics of the single nucleotide polymorphisms 

















T C 0.079358 0.013439 0.860 <0.001 
rs1260326 GCKR C T 0.061666 0.010082 0.361 <0.001 
rs2657879 DDX19B G A 
-
0.221406 
0.012494 0.824 <0.001 
rs6729711 - A G 
-
0.069575 
0.01243 0.819 <0.001 
rs7078003 RBMS2 T C 0.073854 0.011712 0.804 <0.001 
rs7952320 SLC38A4 C G 0.053765 0.009369 0.466 <0.001 
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Table 3 Select Pleiotropic effects of Relevant Glutamine SNPs 
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Figure 3 Leave one Glutamine SNP out Sensitivity Analysis for 















Figure 4 Funnel plot of Relevant SNPs to assess heterogeneity of 
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Cardiovascular disease (CVD) is the leading cause of death 
worldwide. CVD is poorly understood.  Some attention has been 
given in the literature to the cardioprotective effects glycine 
has in humans.  The relationship has primarily been explored in 
clinical and animal models.  Few large observational studies 
have explored the effect of glycine on heart disease.  To 
clarify we assessed whether people with genetically higher 
levels of glycine had lower coronary artery disease (CAD) and 
myocardial infarction (MI) risk. We used a two sample Mendelian 
randomization study. Six SNPs strongly associated (genome wide 
significantly) with glycine were applied to large extensively 
genotyped CAD and MI studies to obtain unconfounded estimates.  
A one standard deviation increase in genetically determined 
glycine was associated with lower risk of  CAD (odds ratio (OR) 
0.94, 95% confidence interval (CI) 0.91-0.98) but not MI (OR 
0.97, 95% CI 0.93-1.02). Sensitivity analysis indicated that the 
IVW estimate might be invalid because of pleiotropy (significant 
p-value for the MR-Egger intercept). After removing pleiotropic 
SNPs the MR-Egger intercept was no longer significant. These 
findings cannot rule out the possibility that glycine is 
cardioprotective and raises new questions of the causal effect 
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of glycine on CAD/MI.  Future research is needed to better 


























Cardiovascular disease (CVD) are the leading cause of death 
worldwide.[1, 2] The World Health Organization (WHO) estimates 
that in 2016, 17,900,00 deaths, or 31% of all deaths, were from 
CVD.[2] In the United States, about one in four deaths, or 
approximately 610,000 deaths, were due to CVDs.[3-5] Coronary 
artery disease (CAD) accounted for 42% of all CVD deaths 
worldwide, or approximately 7.4 million deaths, while CAD 
accounted for about 60% of all CVD deaths in the United States, 
or approximately 375,000 deaths.[3, 4, 6-11] 
 
Observational epidemiological studies have identified numerous 
risk factors for CAD, including hypertension, hyperlipidemia, 
smoking, obesity, diabetes, unhealthy diet, and physical 
inactivity.[12-14] Yet, how these and other factors combine in 
complex causal mechanisms to cause CAD remains poorly 
understood.[6, 25-27] Meta-analyses of observational studies do 
not always draw the same conclusion about the relationship 
between protein consumption and CAD/myocardial infarction 
(MI).[29-32] Furthermore, randomized controlled trials 
(RCTs)[24] that have tested pharmacotherapies capable of 





Glycine is a conditionally-essential amino acid.[39, 40] This 
means that under normal circumstances, the body produces the 
necessary amount of this amino acid for the biosynthesis of 
proteins. However, in conditions such as injury and stress, the 
body may require supplementation of the amino acid through 
dietary intake.[37] Glycine is most notably found in gelatin and 
is a major component of collagen, which is abundant in blood 
vessels and the gut, among other fibrous tissues.[36, 40, 42, 
55, 56] 
 
Glycine is an amino acid involved in anti-oxidative reactions 
and collagen formation.[56] Many studies have shown an inverse 
association of glycine with hypertension and type two 
diabetes.[42] A 2016 clinical study assessed the relationship of 
plasma glycine and acute MI. The authors reported that glycine 
was inversely associated with the risk of MI.[56] They found a 
stronger association in patients with apolipoprotein B, low 
density lipoprotein cholesterol, or apolipoprotein A-1 above the 
median.[56] Other studies have reported the positive effects of 
glycine on vascular health.[42] Glycine has been reported to 
stabilize platelets, reduce the sizes of areas of ischemic 
injury upon reperfusion, correct elevated blood pressure and 
normalize serum triglycerides.[55, 56] While these studies in 
rats and humans reported an inverse relationship with glycine 
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and CAD or CAD-related risk factors, none estimated a causal 
relationship or the underlying pathway by which glycine reduces 
CAD or its related risk factors. 
 
The existing literature is consistent but inconclusive about the 
effects glycine has on CVD and CVD-related risk factors. A large 
RCT with CAD events as the primary outcome would be definitive, 
but costly. Additionally, randomly assigning research 
participants to alter amino acid consumption to determine the 
effect on CAD would be impractical and difficult to implement, 
as modifying diet on a long-term basis presents a compliance 
challenge, and the outcome of interest takes decades to develop. 
It would also take several years and be difficult to justify 
with limited evidence of the benefits of glycine. 
 
A recent study published by Wittemans, Laura B. L. et.al. in 
Nature Communications used MR to estimate the causal 
relationship of glycine with CAD, CAD risk factors and 
diabetes.[124]  The researchers make a compelling case for the 
cardioprotective effect of glycine on CAD.[124]  They also make 
a case for systolic and diastolic blood pressure as a mediator 
between glycine and CAD.[124]   Several differences warrant 
mention.  The study sample used in the recently published study 
expanded on the exposure sample used in our study but may have 
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been affected by heterogeneity between studies due to 
differences metabolomics platforms and in analytical decisions 
between the studies, such as transformation of the glycine 
measures and inclusion of covariates.[124-126] The SNP exposure 
estimates in the previously published study were adjusted for 
age, sex and the first 10 principal components, while my study 
only adjusted for the first 4 principal components.[79, 93, 94, 
124] Thus, raising a question about overfitting the SNP exposure 
model.  The recently published paper developed sex specific 
models adjusting for several covariates, including age, sex, 
genotyping array, testing center and the first 4 principal 
components.  Sex combined associations made no such adjustments.   
Our study also makes no such adjustments in the SNP outcome 
estimates.[79, 93, 94, 124]  However, the recently published 
paper used a weighted median regression MR analysis, while our 
study used IVW MR analysis as the main analysis.  Weighted 
median regression analysis was used only as a sensitivity 
analysis in our study.   Weighted median MR is an 
overidentification method that assume the instrumental variable 
assumptions hold for some of the genetic variants, but not 
necessarily for all genetic variants.[105, 125-129]  Median-
based methods may suggest a positive causal effect despite 
evidence for directional pleiotropy as a result of the relaxed 
assumptions.[105, 125-129]  One issue with down-weighting is 
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that giving less weight to Wald estimates that deviate 
significantly from the majority and standard error of the causal 
effect estimate will be reduced after down weighting those SNPs 
that appear to deviate from the majority.[105, 125-129] This can 
be particularly problematic when no sound biologically plausible 
reason justifies such down weighting as the down-weighted 
outlier may be the most biologically reasonable.[105, 125-129]   
  
 There remains a considerable opportunity to identify new 
casual factors and treatments for CAD/MI. This study will use 
Mendelian randomization (MR) to estimate the effects of glycine 
on CAD/MI. MR has several advantages when compared to 
conventional observational studies and is being increasingly 
used because it overcomes some major limitations of 
observational study designs, including unmeasured confounding. 
MR uses genetic variants as instrumental variables for 
modifiable risk factors that affect population health.[63] The 
principle underlying MR originates from the “The Law of 
Independent Assortment,” also known as Mendel’s second law, 
which states that inheritance of one trait is independent of 
other traits, thus allowing for the use of observational data 
with genetic variants as natural experiments.[63, 64] Genetic 
variants, being fixed at conception, support causal inference by 
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minimizing confounding.[63] MR studies are not influenced by 
confounding due to Mendel’s Law of independent assortment.[60] 
Methods 
As is the case in all analytic approaches, MR depends on three 
assumptions.  The relevance, independence and exclusion 
restriction assumptions are key in selecting valid instrumental 
variables.  The relevance assumption means that the genetic 
instruments predict the exposure reliably. The relevance 
assumption is assured by selecting single nucleotide 
polymorphisms (SNPs) strongly associated with the exposure of 
interest from genome-wide association studies (GWAS).[63] The 
independence assumption means that the genetic instruments are 
not associated with confounders of the exposure outcome 
relation. The independence assumption requires the assessment of 
SNP effects, to minimize the possibility of confounding.[63, 92] 
The exclusion-restriction assumption means that the genetic 
instruments are only associated with the outcome via the 
exposure. The exclusion restriction assumption is assessed from 
biological knowledge of the effects of the genetic instruments, 
known associations of the genetic instruments with other factors 






Genetic associations with glycine 
Genetically determined levels of glycine were obtained from a 
genome-wide association study (GWAS).[93, 94] The Computational 
Medicine extended GWAS combined data from 11 genetic studies and 
14 data sources for a total sample size of 24,925 individuals of 
European descent (Finland, Estonian, Netherlands and 
Germany).[93, 94] The mean age of the study participants was 
44.6 years. The individual study average ages ranged from 31.2 
to 61.3 years. Women were 55% of the total sample, and 
individual study samples ranged from 37% to 64% female.[93, 94] 
Single nucleotide polymorphisms (SNPs) strongly and 
independently associated with glycine (p<5x10-8) were 
selected.[93, 94] The MR-Base “clumping” function was used to 
identify correlations between the chosen SNPs.[95] SNP effects 
on CAD/MI via physiologic pathways other than glycine 
(pleiotropy) were assessed from a comprehensive genotype and 
phenotype cross-references, PhenoScanner.[96, 97] 
Contributed data was corrected for population stratification, 
which has been shown to occur even in single ethnicity 
populations. Ancestry and the non-random distribution of SNPs 
was corrected for using genomic control by adjusting for 





Genetic associations with CAD 
Data on CAD/MI were contributed by the CARDIoGRAMplusC4D. Data 
were downloaded from www.CARDIOGRAMPLUSC4D.ORG. 
CARDIoGRAMplusC4D 1000 Genomes is a CAD and MI case (n=60,801)-
control (n=123,504) study extensively genotyped using the 1000 
Genomes catalog that partially overlaps with CARDIoGRAMplusC4D. 
The majority (77%) of the participants were of European 
ancestry; 13% and 6% were of South Asian (India and Pakistan) 
and East Asian (China and Korea) ancestry, respectively, with 
smaller samples of Hispanic and African Americans.  The mean age 
was about 56.9years, with genetic associations adjusted for 
study specific covariates. Phenotyping of CAD, MI or both was 
based on medical records, clinical diagnosis, procedures that 
indicate CAD, medications or symptoms that indicate angina, or 
self-reporting of CAD. 
 
Statistical analysis 
Associations of glycine with CAD/MI were obtained from separate 
sample instrumental variable analysis with genetic instruments. 
SNP-specific Wald estimates (ratio of SNP on CAD/MI to SNP on 
glycine) of the effect of glycine on CAD/MI were obtained. The 
confidence interval for the Wald estimates were obtained using 




The SNP specific Wald-estimates were combined using inverse-
variance weighting (IVW) with multiplicative random 
effects.[103] The IVW approach is asymptotically equivalent to 
the two-stage least squares (2SLS) estimate commonly used with 
individual-level data and yields comparable causal 




For sensitivity analysis, I used weighted median and MR-Egger 
regression.[104] The weighted-median is a robust alternative 
even in the event of some violations to the IV assumptions. 
Assuming that no single SNP contributes more than 50% of the 
weight to the estimate, this method provides a consistent 
estimate if at least 50% of the weight comes from valid 
IVs.[104] In simulation studies, the weighted-median estimation 
method produces similar point estimates, narrower confidence 
intervals and better finite-sample Type 1 error rates than the 
IVW and the 2SLS method.[104]  
 
The MR-Egger method uses a different, still untestable set of 
assumptions.[104] MR-Egger regression performs well even when 
100% of the IVs are invalid.[104] The slope coefficient from the 
Egger regression method provides an estimate of the causal 
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effect that is consistent asymptotically even if all the genetic 
variants have pleiotropic effects on the outcome; this is known 
as the inSiDe assumption—instrument strength independent of 
direct effect. A stronger genetic variant should have more 
reliable estimates of the causal effect than a weaker variant. 
Once the average pleiotropic effect of variants is accounted for 
through the intercept term in Egger regression, any residual 
dose–response relationship in the genetic associations provides 
evidence of a causal effect. A non-null intercept from MR-Egger 
indicates an invalid IVW estimate.  
 
Analysis was conducted using the TwoSample MR package version 
0.4.14 for R software version 3.5.1, available at 
https://github.com/MRCIEU/TwoSampleMR. Analysis was verified 
using the MR-base platform version 1.2.1 e646be (05 December 
2018), available at http://app.mrbase.org/. This analysis of 
publicly available data did not require IRB approval. 
 
Results 
Genetic determinants of glycine 
Six SNPs identified reached genome wide significance (p<5x10-8). 
All six SNPs found for the exposure were available for the 
outcome.  One palindromic SNP, rs147007805, was aligned using 
the minor allele frequency (MAF).  The MAF threshold was set to 
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0.3. No SNP was in linkage disequilibrium (R2<0.001).  The F-
statistic for SNPs included in the CAD and MI analyses was 
376.75 and SNP specific F-statistic ranged from 33.31 to 
1927.22.[106-108] 
In MR studies obtaining adequate statistical power is frequently 
a concern due to the small amount of variation in a phenotypic 
trait that is typically explained by genetic variants, which is 
addressed by using large samples for the outcome. In a sample 
size of 184,000, assuming the genetic variants explain 2% of the 
variance in glycine, then this study had 80% power to detect an 
OR of 0.907 [106-108] 
 
Association of genetically determined glycine with CAD risk 
Table 1 shows the unconfounded estimate of one standard 
deviation (SD) higher genetically determined glycine was 
associated with decreased risk of CAD. Using the IVW approach, 
the odds of CAD was 0.94 per 1 SD increase in glycine 95% CI 
(0.91-0.98). Sensitivity analysis results obtained using the 
weighted median and MR-Egger produced similar estimates as the 
IVW method, as shown in table 1 and figure 1. Figure 1 shows the 
Wald estimate for each included SNP individually, as well as the 
MR-Egger and IVW regression results for all SNPs combined. 
However, the p-value for the MR-Egger intercept was significant 
suggesting that the IVW estimate is invalid. 
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 The funnel plot in figure 4 does not indicate heterogeneity 
among the SNPs, however, because so few SNPs are included 
symmetry is difficult to assess and an invalid SNP may have been 
included.  
 
Association of genetically determined glycine with MI risk 
Table 1 shows that the effect of one standard deviation (SD) 
higher genetically determined glycine was not clearly associated 
with decreased risk of MI. Using the IVW approach, the odds of 
MI were 0.97 lower among those with genetically determined 
higher levels of glycine than those with lower genetically 
determined glycine, and was not statistically significant 95% CI 
(0.93-1.02). Furthermore, sensitivity analysis results obtained 
using the MR-Egger regression method were not statistically 
significant, and produced similar estimates of no association 
between MI and genetically determined levels of glycine, as 
shown in table 1 and figure 1. However, the p-value for the MR-
Egger intercept was significant suggested that the IVW estimate 
is invalid. 
 
Figure 1 shows the Wald estimate for included SNPs individually, 
as well as the MR-Egger and IVW regression results for all SNPs 
combined. The funnel plot in figure 4 does not indicate 
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heterogeneity among the SNPs, however, the lack of symmetry 
























Figure 1 Wald ratio for individual SNPs and MR-Egger and IVW for 
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Table 1 MR estimates of the associations of log-transformed 
















































Two SNPs, rs1047891 and rs2169387 were associated with 
cholesterol and triglyceride levels, fasting glucose and blood 
pressure.  The remaining SNPs had either no known pleiotropic 
effects or were associated with factors not associated with 
heart disease, such as glaucoma. Table 3 in the appendix shows 
these relations. Estimates were similar after excluding 
rs1047891 and rs2169387.  The IVW estimate CAD was (OR – 0.8861 
, 95% CI 0.788-0.996) and the MR-Egger results were (OR- 0.8772 
, 95% CI 0.771 0.998).  The intercept P-value was 0.569 and the 







This novel study does not exclude the possibility that 
genetically determined glycine is associated with a lower risk 
of CAD. Glycine is most notably found in gelatin and is a major 
component of collagen, which is abundant in blood vessels and 
the gut, among other fibrous tissues.[36, 40, 42, 55, 56] 
Glycine is part of the human diet, with the highest 
concentrations found in shellfish, white fish, pork, turkey and 
chicken skin as well as soybeans.[130] 
Studies, including in vitro, animal and human observational 
studies have shown an inverse association of glycine with CAD 
and CAD risk factors.[42] A 2016 RCT found that glycine was 
inversely associated with the risk of MI.[56] a stronger 
protective effect was found in patients with a level of 
apolipoprotein B, low density lipoprotein cholesterol, or 
apolipoprotein A-1 above the median.[56] Other studies have 
reported positive effects of glycine on vascular health.[42] 
Glycine has been reported to stabilize platelets, reduce the 
sizes of areas of ischemic injury upon reperfusion, correct 
elevated blood pressure and normalize serum triglycerides.[55, 
56]  
 
This study has the advantage of using a novel technique which 
enables estimates to be made cost-effectively even when no study 
 
 19 
including both the exposure and outcome is available. It also 
has the advantage of providing unconfounded estimates.  However, 
MR has stringent assumptions. First, the relevance assumption 
requires that SNPs be strongly associated with the exposure of 
interest.[63]  This study used SNPs that were associated with 
the exposure at a P-value <5 x10-8.  Second, the independence 
assumption requires that SNPs be independent of exposure outcome 
confounders.  This would be expected, as genetic makeup is 
determined a conception and independently from each other.[64] 
Third, the exclusion-restriction assumption requires that the 
SNP affects the outcome only via its effect on the risk factor 
of interest.[63] Known pleiotropy was assessed using 
Phenoscanner and few associations with known CAD/MI risk factors 
were found for the SNPs included in this analysis.[96, 97] Two 
SNPs, rs1047891  and rs2169387 are known to also be associated 
with cholesterol and triglyceride levels, fasting glucose and 
blood pressure.  The remaining SNPs had either no known 
pleiotropic effects or were associated with factors not 
associated with heart disease, such as height. For additional 
information please see the table 3 in the appendix.  Given the 
use of summarized data in two samples, serum glycine levels were 
not measured in the sample with the outcome. However, two-sample 
instrumental variable analysis is more robust to chance 




Making inferences from population based genetic studies, one 
would be concerned with population stratification[83]; when a 
population subgroup experiences different disease and SNP 
frequencies resulting in confounded associations in a whole 
population study. The exposure and outcome data included people 
largely of European descent.  While this study cannot assess the 
effect of glycine on CAD/MI by subgroup, there is no reason to 
think that mechanism by which glycine affects CAD/MI are group 
specific.  Canalization, or developmental compensation occurs 
when molecular mechanisms compensate for the effect of the 
genotype of interest on the outcome of interest.[83]   
Weak instrument bias should not influence results of this 
study.[83]  All included SNPs reach genome wide significance.  
However, a weak instrument would bias results toward the 
null.[119]  Non-linear effects have successfully been identified 
using MR, but depend on additional assumptions.  I had to assume 
a linear relationship in this analysis.  Participant overlap may 
have occurred in this two sample MR analysis.  However, given 
the very large sample size of the exposure and outcome datasets, 
the bias if any should not be of major concern.[26, 120, 121] 
Finally, MR is better at identifying the direction of effect 
rather than its magnitude, though, the entire population is 
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exposed to glycine, making any effect relevant to population 
health.  
Glycine may be associated with a decreased risk of  CAD.  There 
has been evidence since as far back as the 1970’s that that the 
levels of myocardial glycine metabolism change due to myocardial 
ischemia.[34] Glycine is known to stimulate the release of 
insulin from the pancreas, and affects glucose homeostasis.[43] 
Glycine is also been shown to modulate concentrations of nitric 
oxide, a vasodilator; and in at least one study it was 
associated with improved blood pressure.[115, 131] However, 
observational studies have mixed findings.   The INTERMAP study 
showed and inverse relationship of glycine and blood pressure, 
and the Rotterdam study found no significant associations 
between the two.[115, 132, 133]  A recent study evaluated the 
effect of glycine on atherogenesis using murine 
macrophages.[114]  Glycine showed clear anti-atherogenic 
effects, by significantly reducing macrophage triglyceride 
content, related to decreased VLDL uptake.[114] Glycine was the 
only amino acid that attenuated both the uptake of the 
triglyceride-rich VLDL and the triglyceride biosynthesis rate in 
macrophages.[114] there is some evidence that the effect glycine 
has on CVD differs by sex.  A 2016 study found that there was an 
inverse relationship between glycine and acute MI and was more 
favorable among women than men.[134]    Several biological 
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pathways have been hypothesized explaining the potential 
positive effect that glycine has on CAD, including increasing 
intracellular antioxidants, thus having a positive effect on 
vascular health. Glycine intake counteracts many of the adverse 
effects of a high-sucrose diet on the liver, adipose mass and 
vascular function in rats.[55]  Glycine decreased the fatty acid 
content of the liver of sucrose-fed rats, corrected an elevation 
of blood pressure, normalized the serum triglycerides and 
insulin, and, in the vasculature, boosted glutathione, decreased 
oxidative stress and normalized endothelium-dependent 
vasodilation.[55]  Glycine may stimulate  and glucagon release 
and decrease membrane polarization in cells.[55] This may be why 
when glucose was fed to patients with type 2 diabetes in 
conjunction with gelatin it strengthened the insulin 
response[55] Clinically, glp-1 agonist drugs promote modest 
weight loss in patients, and exert favorable effects on systolic 
blood pressure, serum lipids, inflammatory markers and 










This study does not exclude the possibility that genetically 
determined glycine is associated with a lower odd of CAD.[46] We 
replicate a similar study conducted by Wittemans, Laura B. L. 
et.al. in Nature Communications that used MR to estimate the 
causal relationship of glycine with CAD, CAD risk factors and 
diabetes.[124].  Although both studies conducted a MR of glycine 
on cardiovascular disease Several differences exist between the 
two, including the use of different MR methods, population 
sizes, outcomes and homogeneity.  The recently published MR 
study found glycine to be cardioprotective.[124]  That same 
study found that the protective effect of glycine on CAD was 
mediated via improved blood pressure.[124]  
 
Glycine is generally found in the skin, bones and organs of some 
animals.  Because most people do not eat these parts of an 
animal, glycine can be modified via dietary supplements along 
with what is part of a normal diet.  Additional research is 
needed to conclusively establish glycine is statistically 
significantly associated with lower risk of CAD, and via what 







Table 2 Characteristics of the single nucleotide polymorphisms 
























rs10083777 CENPN T C -0.10606 0.01 0.827109  
rs1047891 CPS1 A C 0.487116 0.01 0.666106  
rs13298772 KIAA2026 C T 0.273079 0.02 0.946912  
rs147007805 MAP2 A T -0.14046 0.02 0.925411  




G A -0.13006 0.02 0.13332  
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Table 3 Select Pleiotropic effects of Relevant Glycine SNPs 
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Figure 4 Funnel plot of Relevant SNPs  to assess heterogeneity 
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Observational epidemiologic studies are susceptible to 
confounding and selection bias.[103, 135] The strength of a 
Mendelian randomization (MR) analysis is that it leverages the 
natural randomization that is inherent in the assignment of 
genetic information at birth increasing the robustness of causal 
inference.[103, 135] Observational studies and RCTs have 
contributed to the reduction of CHD and MI that has occurred in 
western settings in recent decades. Despite these improvements, 
cardiovascular diseases, including CHD and MI remain the leading 
causes of death.[60] Opportunity remains to identify new casual 
factors and treatments for CAD/MI.  This study used MR to 
estimate the effects of three amino acids on CAD/MI. 
 
This study is the first MR study to assess the relationship of 
CAD/MI with alanine and glutamine. This study also replicates an 
analysis of CAD/MI with glycine, strictly adhering to the MR 
assumptions. After an extensive literature review, it was 
hypothesized that alanine, glutamine and glycine would all have 
a cardioprotective effect. Glutamine, glycine, and alanine have 
been established in animal studies to be linked with heart 
function and heart disease.[34-36, 40-42, 45-48]  Glutamine is 
commonly found in nuts, which observational studies and RCTs 
 
 1 
have found to be cardio-protective.[44, 49-51] Animal model and 
small RCT studies have found that glutamine improves 
postoperative outcomes and restores the heart to normal function 
more quickly than without glutamine supplements.[38, 47, 48]  
Similarly, glycine studies have shown an inverse relationship 
with CAD and CAD risk factors such as hypertension. Alanine 
studies have shown an inverse relationship with diabetes, a risk 
factor for CAD, in light of the beneficial role that alanine 
plays in glucose homeostasis and the increased alanine observed 
during cardiac events.[52-54] 
 
Alanine 
Analysis in this dissertation found that alanine might lower the 
risk of CAD.  The unconfounded estimate of one standard 
deviation (SD) higher genetically determined alanine was 
associated with lower risk. Using the IVW approach, the odds of 
CAD was 0.89 lower among those with genetically determined 
higher levels of alanine than those with lower genetically 
determined alanine and was statistically significant (95% 
confidence interval (CI) (0.80-0.99)and the odds of MI was 0.90 
lower per SD increase of alanine (95% CI (0.800-1.015). 
Sensitivity analysis results obtained using the weighted median 
and MR-Egger regression method were not statistically 
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significant, though the effect was in the same protective 
direction as was found in the IVW method for both CAD and MI. 
Beta-alanine is known to increase muscle carnosine levels.[35, 
36, 52, 53, 85, 113, 116] Carnosine is widely considered an 
important anti-glycating agent, potentially improving energy 
metabolism and protein homeostasis.[113]  Improved handling of 
glycation end products has had promising results with diabetes 
complications, a CAD risk factor.[113] Additionally, carnosine 
has antioxidative properties, which are thought to improve heart 
health.[90, 113]   
Glutamine 
Analysis in this dissertation found that one standard deviation 
(SD) higher genetically determined glutamine was not clearly 
associated with CAD or MI. Using the IVW approach, the odds of 
CAD was 1.09 higher per 1 SD increase in glutamine but was not 
statistically significant 95% confidence interval (CI) (0.99-
1.19) and the odds of MI was 1.05 higher per one SD increase in 
glutamine but was not statistically significant 95% confidence 
interval (CI) (0.99-1.19). Sensitivity analysis results obtained 
using the weighted median and MR-Egger regression method were 
statistically significant for both CAD and MI, with a similar 
odds ratio estimate as the IVW method.  The sensitivity analysis 
also indicated that the IVW estimate for CAD and MI might be 
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invalid because the p-value for the MR-Egger intercept was 
significant.  
 
The role of glutamine in CAD and MI is unclear.  A study  found 
glutamine a reliable discriminator of CAD and non-CAD among 
cardiac catheterization patients.[114, 122] Glutamine has also 
been associated with plaque development and intima–media 
thickness.[114, 115, 123] Some in vitro and animal studies have 
found that glutamine levels have been associated with 
atherosclerosis and CAD risk. [114]  Glutamine stimulates the 
accumulation of triglycerides in microphages by affecting the 
SREBP-1, a key regulator in cellular triglyceride 
biosynthesis.[114] Furthermore, glutamine stimulates microphage 
oxidative stress, affecting lipid metabolism.[114]  The 
direction of effect that glutamine has on CAD and MI remains 
unclear and should be conclusively evaluated in a large RCT 
study to confirm that glutamine is a risk factor for CAD and MI. 
Glycine 
Analysis in this dissertation found that one standard deviation 
(SD) higher genetically determined glycine 
 was not clearly associated with increased risk for CAD or MI. 
Using the IVW approach, the odds of CAD was 0.94 per 1 SD 
increase in glycine 95% CI (0.91-0.98) and odds of MI was 0.97 
lower among those with genetically determined higher levels of 
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glycine and was not statistically significant 95% CI (0.93-
1.02). Sensitivity analysis results produced similar estimates 
however, the p-value for the MR-Egger intercept was significant 
suggesting that the IVW estimate is invalid. 
 
Glycine may protect against CAD. Several biological pathways 
have been hypothesized explaining the potential positive effect 
that glycine has on CAD, including increasing intracellular 
antioxidants. Glycine intake counteracts many of the adverse 
effects of a high-sucrose diet on the liver, adipose mass and 
vascular function in rats and decreased the fatty acid content 
of the liver of sucrose-fed rats, corrected an elevation of 
blood pressure, normalized the serum triglycerides and insulin, 
and, in the vasculature, boosted glutathione, decreased 
oxidative stress and normalized endothelium-dependent 
vasodilation.[55]  Glycine may stimulate  and glucagon release 
and decrease membrane polarization in cells.[55] This may be why 
when glucose was fed to patients with type 2 diabetes in 
conjunction with gelatin it strengthened the insulin 
response[55] This analysis replicates the study conducted by 
Wittemans, Laura B. L. et.al., but uses IVW rather than a 
weighted median approach to obtain unconfounded estimates.[124] 
The IVW method strictly adheres to the assumptions required of a 
valid MR analysis, possibly explaining the difference in the 
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significance of the effect observed in the two analyses.   The 
recently published MR study found glycine to be 
cardioprotective.[124]  My analysis could not rule out the 
possibility of a cardioprotective effect, however additional 
research is needed to conclusively establish glycine as 




This study has several limitations.  MR analysis makes a number 
of assumptions, which if incorrect can affect the results and 
subsequent conclusions. There is an unlikely possibility for 
confounding by population stratification. However, the sample 
used for this study is mostly homogeneous, made up 
overwhelmingly of people of European descent. Pleiotropic 
effects, or violation of the exclusion-restriction assumption, 
occur when the chosen genetic variant has a direct effect on the 
outcome of interest via a pathway other than the exposure of 
interest.  The two-sample analytic approach means I used summary 
data about the relationship of the genetic variant to the 
exposure of interest from one sample and summary data about the 
relationship between the genetic variant and the outcome of 
interest to determine the relationship between the exposure and 
outcome. By design, the exposure of interest and the outcome are 
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not measured in the same sample. This limits my ability to 
perform a rigorous subgroup analysis. However, the two-sample 
method is more robust to chance associations than one sample 
analyses.  Additionally, use of summary data from two samples 
may result in sample overlap, which could bias the findings. The 
sample size of both data sources is very large, and bias due to 
sample overlap is not of major concern. The use of summary data 
also makes it difficult to test whether associations vary by 
sub-group. Although causal effects should be consistent they may 
not be relevant in all populations.[136] Similarly, Mendelian 
randomizations estimates for the effects of these amino acids 
may vary according to their levels in different populations.  
Finally, the NO Measurement Error (NOME) assumption, 
specifically that there is no measurement error in the genetic 
variant and exposure association, cannot be tested directly. An 
adaptation of the I2 statistic from the field of meta-analysis 
is proposed to quantify the strength of NOME violation for MR-
Egger.[127] 
One additional limitation of this study, and MR in general, is 
that in most instances it specifies the endogenous effect on the 







The dissertation contributes to knowledge of CAD and MI by using 
a novel analytic method to obtain unconfounded estimates for 
three amino acids where the epidemiological, clinical, and in 
vitro studies have been inconclusive.  It has the advantage of 
using a novel technique which enables estimates to be made cost-
effectively even when no study including both the exposure and 
outcome is available. MR is not well suited for assessing the 
magnitude of the effect, but rather the direction of the effect.   
The statistically significant lower risk of CAD with higher 
alanine requires replication to more clearly understand the 
magnitude and pathway by which alanine affects CAD in order to 
develop targeted treatments and pharmacotherapies.[76]  The 
analyses for glutamine and glycine did not have statistically 
significant findings, and is a call for additional studies, 
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